---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-060795"
form_type: "8-K"
ticker: null
cik: "0001845459"
company_name: "NKGen Biotech, Inc."
filed_at: "2024-07-12T23:59:59+00:00"
generated_at: "2026-05-31T21:20:40.538737+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# NKGen Biotech appoints Dr. Marco Gottardis to Board of Directors

## Summary
- Dr. Gottardis fills Class I director vacancy created by Alana McNulty's resignation, effective July 11, 2024.
- Appointed to Audit, Compensation, and Nominating committees; annual retainer of $40,000 plus committee retainers.
- Received sign-on option for 300,000 shares at $2.00 per share, vesting monthly over three years.
- Background: former VP of Oncology Innovation at Janssen (JNJ) and Senior VP at Replay Bio Holdings.

## SEC filing metadata
- accession: 0001213900-24-060795
- form_type: 8-K
- cik: 0001845459
- company_name: NKGen Biotech, Inc.
- filed_at: 2024-07-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845459/000121390024060795/0001213900-24-060795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845459/000121390024060795/ea0209333-8k_nkgen.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-060795
- JSON: https://secwatch.observer/filing/0001213900-24-060795.json
- Plain text: https://secwatch.observer/filing/0001213900-24-060795.txt

## Key facts
- Executive change
  Dr. Marco Gottardis was elected as Director at NKGen Biotech, Inc..
  - Action: elected
  - Role: Director
  source text: On July 11, 2024, the Board, following a recommendation from the N&CG Committee, unanimously elected to have Dr. Marco Gottardis fill, effective immediately, the Class I director vacancy created by Ms. McNulty’s resignation and that Dr. Gottardis shall hold such position as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390024060795/0001213900-24-060795-index.htm
- Executive change
  Alana McNulty resigned as Director at NKGen Biotech, Inc..
  - Action: resigned
  - Role: Director
  source text: Ms. Alana McNulty notified the Board of Directors of the Company (the “Board”) of her intention to resign as a director of the Company and as a member of our Audit Committee (the “Audit Committee”), Compensation Committee (the “Compensation Committee”) and Nomination and Corporate Governance Committee (the “N&CG Committee”), effective February 4, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845459/000121390024060795/0001213900-24-060795-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.